EUREPA 1MG TABLET contains Repaglinide which belongs to the group of medicines called Antidiabetics. It is used to treat type 2 diabetes as an adjunct to diet and exercise.
Type 2 diabetes is a disease condition in which the pancreas does not make enough insulin to control sugar in the body or the body does not react well to insulin that is produced thus, leading to high blood glucose levels. The symptoms of high blood sugar level are feeling thirsty, increased urination, dry skin, and dry mouth.
Along with the treatment with EUREPA 1MG TABLET your doctor may advise you to make some lifestyle changes such as having a balanced diet, good sleep, exercising. Before starting the treatments with EUREPA 1MG TABLET your doctor would want you to take some diagnostic tests.
EUREPA 1MG TABLET is not recommended in patients who have severe liver disease, diabetes type 1 and diabetic ketoacidosis. Consult your doctor for advice.
Patients having moderate liver diseases, kidney problems or are about to have a surgery should take EUREPA 1MG TABLET with caution.
EUREPA 1MG TABLET should not be taken by pregnant or breast-feeding women, children and adolescents below 18 years of age.
It is also not recommended for use in elderly patients above 75 years of age. The most common side-effects of EUREPA 1MG TABLET are hypoglycaemia, stomach pain and diarrhoea. Talk to your doctor if these worsen or doesn’t improve.
EUREPA 1MG TABLET helps in reducing the blood sugar levels by acting on specific cells (beta cells) present in the pancreas and increases the release of insulin. Insulin is responsible for bringing the blood sugar levels down.
Take EUREPA 1MG TABLET as advised by your physician. Swallow the medicine with a glass of water. Do not crush or chew the medicine. Your doctor will decide the correct dose and duration for you depending upon your age, body weight and disease condition.
Stop taking EUREPA 1MG TABLET if you experience any of the following side effects and talk to your doctor immediately:
Diarrhoea:
Drink lots of fluids, such as water or fruit juice to keep yourself hydrated. Do not consume any medicine on your own without consulting your doctor.
Stomach pain:
Try to rest and relax. Eat and drink slow or try to have smaller and frequent meals. Keep a heat pad on your stomach. If the symptom does not improve, contact your doctor.
EUREPA 1MG TABLET is not recommended for use in pregnant women. Consult your doctor before taking it.
EUREPA 1MG TABLET is not recommended for use in breastfeeding women. Consult your doctor before taking it.
Do not drive or use machineries after taking EUREPA 1MG TABLET if you feel a hypoglycaemic state. Consult your doctor.
Avoid the consumption of alcohol as it may change the ability of EUREPA 1MG TABLET to lower down blood sugar. Consult your doctor for advice.
EUREPA 1MG TABLET should be taken with caution in patients with kidney disease. Consult your doctor before taking.
EUREPA 1MG TABLET is generally not recommended in patients with severe liver disease. It should be used with caution in patients with moderate liver disease. Consult your doctor before taking the medicine.
Do not take EUREPA 1MG TABLET if you are allergic to Repaglinide or any ingredients of this medicine.
EUREPA 1MG TABLET is not recommended for use if you:
Before taking EUREPA 1MG TABLET inform your doctor if you:
Use in pediatrics:
EUREPA 1MG TABLET is generally not recommended for use in children and adolescents (under 18 years of age). Consult your doctor before taking.
Use in geriatrics:
EUREPA 1MG TABLET should be used with caution in elderly patients above 75 years of age. Consult your doctor before taking.
A. Drug-Drug Interactions:
Overdosage:
If you or anyone else accidentally takes too much of EUREPA 1MG TABLET it can lead to hypoglycaemia. Inform your doctor immediately or visit the nearby hospital. Symptoms of overdosage of EUREPA 1MG TABLET are cold sweat, cool pale skin, headache, fast heartbeat, nausea, feeling very hungry, temporary changes in vision, drowsiness, unusual tiredness and weakness, nervousness or tremor, feeling anxious and confused, and difficulty in concentrating.
Drug | : | Repaglinide |
Pharmacological Category | : | Meglitinides |
Therapeutic Indication | : | Type 2 Diabetes mellitus |
Dosage Forms | : | Tablet |
Can EUREPA 1MG TABLET be used alone to treat diabetes mellitus type 2?
No. EUREPA 1MG TABLET is used in the treatment of diabetes mellitus type 2 or non-insulin dependent diabetes mellitus as an adjunct to diet or when diet and other sugar lowering medications are not working enough. Your doctor will be able to better understand your condition and treat accordingly.
Is overdose of EUREPA 1MG TABLET likely to cause hypoglycaemia (abnormally low blood sugar)?
Yes. overdose of EUREPA 1MG TABLET may cause hypoglycaemia. Symptoms of overdosage of EUREPA 1MG TABLET are cold sweat, cool pale skin, headache, fast heartbeat, drowsiness, unusual tiredness and weakness, nausea, feeling very hungry, temporary changes in vision, nervousness or tremor, feeling anxious and confused, and difficulty in concentrating. If you or anyone else happens to have an overdose of EUREPA 1MG TABLET contact your doctor immediately.
What to do if I forget to take a dose of EUREPA 1MG TABLET?
If you forgot to take a dose of EUREPA 1MG TABLET then do not take the missed dose between meals. Wait until your next scheduled dose and meal and continue taking your medicine as per normal. Do not take a double dose of EUREPA 1MG TABLET to make up for a forgotten dose. Consult your doctor.
Can I stop taking EUREPA 1MG TABLET on my own?
No. You should not stop taking EUREPA 1MG TABLET without the advice of the doctor. If you do so, the desired effect may not be achieved, and your blood sugar level can happen to rise again.
Can EUREPA 1MG TABLET be used in children and adolescents?
No. EUREPA 1MG TABLET is not recommended to use in children and adolescents (below 18 years of age). Consult your doctor.
1. KD. Tripathi. Insulin, Oral Hypoglycaemic Drugs and Glucagon. Essentials of medical pharmacology. Seventh edition. 2013. Page – 273.
2. Zara Milner, Hossein Akhondi. Repaglinide. NIH National Library of Medicine, National center for biotechnology information. Jan 2022. [Accessed on 25th May 2022] https://www.ncbi.nlm.nih.gov/books/NBK559305/#article-93347.s3
3. Accord Healthcare. Electronic Medicines Compendium (EMC). [Revised in Jan 2019]. [Accessed on 25th April 2022] https://www.medicines.org.uk/emc/files/pil.4629.pdf
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.